Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dalton Supports Client Milestone in Dengue Treatment Clinical Trial

Published: Tuesday, August 07, 2012
Last Updated: Tuesday, August 07, 2012
Bookmark and Share
Completes API development and manufacture for Phase I trial.

A clinical trial to treat dengue fever with a new antiviral medicine, Celgosivir, has been initiated in Singapore.

The trial follows successful mouse model studies by researchers at the Duke-National University of Singapore (NUS) Graduate Medical School, who established its efficacy.

Celgosivir, also known as butyl-castanospermine, is derived from the seeds of the Moreton Bay Chestnut tree.

The Phase 1b clinical trial to evaluate Celgosivir as a treatment Against Dengue (CELADEN) has opened for enrolment at the Singapore General Hospital’s Investigational Medicine Unit.

This follows the successful completion of development of the active pharmaceutical ingredient (API) and manufacturing of the final dosage form by Dalton Pharma Services and subsequent approval for the clinical trial by the Health Sciences Authority of Singapore and the hospital’s Institutional Review Board.

Associate Professor Subhash Vasudevan who directs the Emerging Infectious Diseases Therapeutics Laboratory at Duke-NUS, is investigating Celgosivir as a potential treatment for dengue fever and also for its ability to prevent severe symptoms that are known to lead to Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS).

According to estimates by the World Health Organization (WHO), about 2.5 billion people, or 40% of the world's population, live in areas at risk of dengue transmission.

About 500,000 cases of severe dengue (DHF/DSS) occur annually, resulting in about 24,000 deaths, predominantly amongst the young. There are no approved medicines to treat dengue fever.

Dalton Pharma Services successfully completed a comprehensive drug development program for the CELADEN trial, which included Celgosivir process development, cGMP API and capsule manufacturing, as well as validations, analytical, and stability studies, in support of Duke-NUS’s translational clinical research program.

“We are pleased to have reached this important milestone with the support of Dalton Pharma Services,” remarked Dr. Cynthia Sung, project manager for the CELADEN trial. “They were able to develop the active ingredient and produce GMP clinical materials, which helped us to get it into the clinic for this important trial. Their integrated approach and experience in moving early stage projects forward really streamlined the process for us.”

"We are very grateful for the opportunity to contribute to the progress of this key project with our customer Duke-NUS. Dalton hopes to continue to support Duke-NUS in their ongoing efforts to bring important new medicines to the world," said Peter Pekos, CEO of Dalton Pharma Services.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dalton Receives Notice of Award from NIDA of NIH to Fund Research
The goal of the research work is to identify and establish candidates for further development towards a future drug product.
Friday, September 06, 2013
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
New Skin Cancer Drugs with Surprising Powers
Inserm team synthesizes and developed new drugs for melanoma.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!